Compare SAIC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIC | RCUS |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2013 | 2018 |
| Metric | SAIC | RCUS |
|---|---|---|
| Price | $133.33 | $25.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $110.50 | $31.90 |
| AVG Volume (30 Days) | 463.8K | ★ 1.4M |
| Earning Date | 06-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 7.39 | N/A |
| EPS | ★ 5.00 | N/A |
| Revenue | ★ $7,262,000,000.00 | $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.65 | $45.62 |
| P/E Ratio | $26.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $81.08 | $12.15 |
| 52 Week High | $142.66 | $31.74 |
| Indicator | SAIC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 36.79 |
| Support Level | $123.20 | $23.91 |
| Resistance Level | $142.66 | $26.43 |
| Average True Range (ATR) | 4.58 | 1.22 |
| MACD | 0.29 | -0.45 |
| Stochastic Oscillator | 52.43 | 26.16 |
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management, operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments, which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.